| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2014-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a62764b288fd78fdd5859922aa67a9a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a20c5335fa21e8580e38b55436ebc91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f45bd1c9921fe8d4d5fa185f028fbf2 |
| publicationDate |
2016-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20160058184-A |
| titleOfInvention |
Enzalutamide in combination with afuresertib for the treatment of cancer |
| abstract |
The present invention relates to an androgen receptor inhibitor, for example 4- (3- (4-cyano-3- (trifluoromethyl) phenyl) -5,5-dimethyl- -1-yl) -2-fluoro-N-methylbenzamide or a pharmaceutically acceptable salt thereof and an AKT inhibitory compound such as N - {(1S) Phenyl) methyl] ethyl} -5-chloro-4- (4-chloro-1-methyl-1H-pyrazol-5-yl) -2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof, A novel combination comprising an anti-neoplastic agent; A pharmaceutical composition comprising the same, and methods of using such combinations and compositions in the treatment of conditions in which androgen receptor inhibition and / or AKT inhibition are beneficial, for example, in the treatment of cancer. |
| priorityDate |
2013-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |